Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -32.15% is 25% above its 5-year average of -42.63%, around the middle of its 5-year range (-87.66%–6.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 45.21% above its 12-month average of -58.68%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.15%.
RETURN ON INVESTED CAPITAL (ROIC)
-32.15%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-58.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-57.79%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-42.63%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-51.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.21%
CURRENT VS 3Y AVG
+44.37%
CURRENT VS 5Y AVG
+24.58%
CURRENT VS 10Y AVG
+37.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+9.81%
vs the sector median at left
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Return on Invested Capital (ROIC)
-32.15%
TTM Avg
-58.68%
3Y Avg
-57.79%
5Y Avg
-42.63%
Market Cap
$1.54B
Return on Invested Capital (ROIC)
8.36%
TTM Avg
8.44%
3Y Avg
9.74%
5Y Avg
16.58%
Market Cap
$1.57B
Return on Invested Capital (ROIC)
-63.12%
TTM Avg
-24.75%
3Y Avg
-38.52%
5Y Avg
-35.23%
Market Cap
$1.50B
Return on Invested Capital (ROIC)
33.76%
TTM Avg
23.76%
3Y Avg
-16.29%
5Y Avg
5.45%
Market Cap
$1.50B
Return on Invested Capital (ROIC)
20.41%
TTM Avg
-2.25%
3Y Avg
-13.09%
5Y Avg
-29.56%
Market Cap
$1.59B
Return on Invested Capital (ROIC)
-47.99%
TTM Avg
-42.50%
3Y Avg
-275.02%
5Y Avg
-275.02%
Market Cap
$1.49B
Return on Invested Capital (ROIC)
-35.66%
TTM Avg
-26.24%
3Y Avg
-27.95%
5Y Avg
-27.95%
Market Cap
$1.48B
Return on Invested Capital (ROIC)
11.91%
TTM Avg
9.57%
3Y Avg
7.02%
5Y Avg
7.35%
Market Cap
$1.60B
Return on Invested Capital (ROIC)
-22.55%
TTM Avg
-30.11%
3Y Avg
-30.00%
5Y Avg
-19.97%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | -32.15% | -58.68% | -57.79% | -42.63% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.36% | 8.44% | 9.74% | 16.58% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -63.12% | -24.75% | -38.52% | -35.23% |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 33.76% | 23.76% | -16.29% | 5.45% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 20.41% | -2.25% | -13.09% | -29.56% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -47.99% | -42.50% | -275.02% | -275.02% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | -35.66% | -26.24% | -27.95% | -27.95% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 11.91% | 9.57% | 7.02% | 7.35% |
| uniQure N.V. (QURE)vs › | $1.60B | -22.55% | -30.11% | -30.00% | -19.97% |
| GH Research PLC (GHRS)vs › | $1.48B | -19.87% | -24.87% | -20.19% | -15.68% |
ROIC
-32.1%
ROE
-1462.1%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -32.15% |
| 2026-03-31 | -57.84% |
| 2025-12-31 | -66.60% |
| 2025-09-30 | -66.64% |
| 2025-06-30 | -70.17% |
| 2025-03-31 | -62.97% |
| 2024-12-31 | -53.63% |
| 2024-09-30 | -87.66% |
| 2024-06-30 | -66.13% |
| 2024-03-31 | -53.41% |
| 2023-12-31 | -41.45% |
| 2023-09-30 | -53.75% |
| 2023-06-30 | -43.09% |
| 2023-03-31 | -36.86% |
| 2022-12-31 | -32.41% |
| 2022-09-30 | -4.12% |
| 2022-06-30 | 0.30% |
| 2022-03-31 | 4.18% |
| 2021-12-31 | 6.11% |
| 2021-09-30 | -40.58% |
| 2021-06-30 | -36.29% |
| 2021-03-31 | -32.14% |
| 2020-12-31 | -25.15% |
| 2020-09-30 | -40.07% |
| 2020-06-30 | -32.78% |
| 2020-03-31 | -66.96% |
| 2019-12-31 | -127.42% |
| 2019-09-30 | -107.88% |
| 2019-06-30 | -96.37% |
| 2019-03-31 | -84.72% |
| 2018-12-31 | -111.86% |
| 2018-09-30 | -95.70% |
| 2018-06-30 | -85.55% |
| 2018-03-31 | -66.50% |
| 2017-12-31 | -51.04% |
| 2017-09-30 | -48.61% |
| 2017-06-30 | -43.36% |
| 2017-03-31 | -55.60% |
| 2016-12-31 | -44.37% |
| 2016-09-30 | -34.36% |
| 2016-06-30 | -23.02% |
| 2016-03-31 | -19.22% |
| 2015-12-31 | -24.12% |
| 2015-09-30 | -19.60% |
| 2014-12-31 | -239.17% |
| 2014-09-30 | -262.44% |
| 2014-06-30 | -307.07% |
| 2014-03-31 | -102.22% |
| 2013-12-31 | -59.81% |
